Insights On Upstream Manufacturing

  1. Top 5 Barriers To Scalable ncAA Conjugation And What's Finally Changing 5/5/2026

    Examine data from an anti-GPCR VHH program that shows how ncAA conjugation barriers, like yield loss, toxicity, incomplete incorporation, can be overcome at scale.

  2. Solving The DNA Knock-In Problem 5/1/2026

    An in‑depth exploration of why large, precise DNA knock‑ins limit cell therapy progress—and how site‑specific integration enables durable, scalable genetic engineering solutions.

  3. Expanding The Capabilities Of Targeted Integration 5/1/2026

    See the demonstration of precise, site‑specific integration of a 50 kb multi‑gene construct into human iPSCs, overcoming size limits of traditional genome‑engineering approaches.

  4. Redefining Cell Line Development For Next-Generation Biologics 4/30/2026

    A transposon‑enabled cell line development strategy streamlines upstream optimization, shortening timelines while improving consistency, yield, and quality across recombinant protein modalities.

  5. From DNA To IND In As Little As 6 Months 4/27/2026

    Discover how an integrated, platform-driven CMC approach can accelerate your antibody program from DNA to IND in as little as six months while reducing risk and maintaining quality and regulatory alignment.

  6. ESACT 2026: Reducing Variability With Animal‑Origin‑Free Peptones 4/24/2026

    Explore how data‑driven collaboration and animal‑origin‑free media strategies can reduce variability, improve cell culture performance, and support consistent, cost‑effective bioprocessing at scale.

  7. Providing Solutions In Titer, Host Cell Protein, And Scalability 4/23/2026

    By leveraging expertise across a global network and executing a streamlined, rapid technology transfer, see how we were able to enable a highly data-driven approach to clone selection and process optimization.

  8. Scale Up Or Scale Out? Choosing An Adherent Cell Culture Platform 4/21/2026

    Facility space costs up to $1,000/sq ft and planning timelines stretch 18 months, making your adherent cell culture platform choice one of the highest-stakes decisions in vaccine manufacturing scale-up.

  9. Aligning Upstream And Downstream Development (Part 1) 4/20/2026

    In this episode of “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their conversation about how upstream and downstream development teams can work together to accelerate timelines and reduce risks and bottlenecks in process development.

  10. Where Sourcing Meets Science: Smarter Collaboration, Better Outcomes 4/20/2026

    See how collaboration-driven raw material control reduces variability, improves cell culture performance, and delivers measurable cost and productivity gains in biotherapeutic manufacturing.